Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
Location status: Recruiting
Location contact
Myung Jin Song, MD.PhD
CONTACT
82+1045990531
Sung Yoon Lim, MD PhD
CONTACT
82+1028469179
NCT Number: NCT07539883
This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.
Interested in participating?
Request Info19 year and older
All sexes
Observational
Seongnam-si, Gyeonggi-do, 13620, South Korea
Location status: Recruiting
Myung Jin Song, MD.PhD
CONTACT
82+1045990531
Sung Yoon Lim, MD PhD
CONTACT
82+1028469179
Background:
Septic shock is characterized by a dysregulated host response to infection, leading to a "cytokine storm" that causes organ dysfunction and hemodynamic instability. Extracorporeal blood purification (EBP) using the oXiris® filter is designed to restore immune homeostasis by adsorbing both endotoxins and cytokines while performing standard CRRT functions. However, existing observational data often suffer from selection and immortal time biases.
Study Design and Methodology:
This study employs the Target Trial Emulation (TTE) framework to mimic the design of a randomized controlled trial using retrospective observational data.
Strategy A (oXiris): CRRT initiated with the oXiris® filter. Strategy B (Control): CRRT initiated with a standard filter, sourced from the Korea Sepsis Alliance registry.
To adjust for baseline confounding and confounding by indication, propensity score-based Inverse Probability of Treatment Weighting (IPTW) will be applied.
Primary Outcome: In-hospital mortality will be analyzed using an IPTW-weighted Cox proportional hazards model.
Secondary Outcomes:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From the initiation of CRRT (Time zero) until hospital discharge or death.
The primary objective is to evaluate the causal effect of oXiris® hemofilter use on survival during the hospital stay compared to standard CRRT. Statistical analysis will be performed using an Inverse Probability of Treatment Weighting (IPTW)-weighted Cox proportional hazards model to adjust for baseline and time-varying confounders.
Time frame: 3 days after CRRT initiation.
Comparison of the total fluid intake and output over the first 3 days after CRRT initiation.
Time frame: From CRRT initiation through ICU discharge, up to 28 days
The duration from CRRT initiation until the successful discontinuation of all vasopressors.
Time frame: Baseline (Day 0) and Days 1, 2, 3, 7 of ICU stay.
Evaluation of organ failure improvement through repeated measures of the Sequential Organ Failure Assessment (SOFA) score.
Time frame: Baseline (Day 0) and Days 1, 2, 3, 7 of ICU stay.
Assessment of the reduction in serum levels of CRP, Procalcitonin, and lactate.
Time frame: From CRRT initiation through hospital discharge, up to 90 days
Proportion of patients who recover renal function and do not require renal replacement therapy at the time of hospital discharge.
Contact information is provided by the study sponsor or research team.
Myung Jin Song, MD.PhD
CONTACT
82+1045990531
Sung Yoon Lim, MD. PhD
CONTACT
82+1028469179
Seoul National University Bundang Hospital
Other
Official Title: Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study Using a Target Trial Emulation Approach
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05874895
Infections, Inflammation
Ostrava, Moravian-Silesian Region, Czechia
View Trial DetailsNCT04695119
Cardiomyopathies, Cardiovascular Diseases
Dijon, France
View Trial DetailsNCT07369206
Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Failure
Erzurum, Turkey (Türkiye)
View Trial DetailsNCT06808100
Infections, Inflammation
Ankara, Turkey (Türkiye)
View Trial Details